Hepatitis B&C Training Program and Treatment Update 2018 - Universal City
In-Person Event
Oct 06, 2018
Universal City, California, USASpeakers
OVERVIEW
Hepatitis B&C Training Program and Treatment Update 2018 is organized by Scripps Health and will be held on Oct 06, 2018 at Sheraton Universal Hotel, Universal City, California, United States of America. This CME Conference has been approved for a maximum of 7 AMA PRA Category 1 Credits.
Course Description:
The Scripps National Hepatitis B & C Training Program and Treatment Update will contribute towards increasing the number of health care practitioners educated on the prevalence of chronic viral hepatitis, as well as those properly preventing, diagnosing, treating, and/or referring patients with chronic illness; therefore contributing towards prevention of new cases and improved management of already infected patients.
Viral hepatitis is the seventh leading cause of death in the world, killing more people than traffic injuries, HIV and AIDS, or diabetes. Every year chronic viral hepatitis, of which hepatitis B and C are the most common forms, kills a million people, roughly 20,000 of them in the United States. These deaths could be prevented. Hepatitis B vaccine conveys 95 percent immunity, and new therapies for hepatitis C cure the vast majority of patients. A report from the National Academies of Sciences, Engineering, and Medicine, released in April, 2016 concluded that both hepatitis B and C could be rare diseases in the United States, and a report from the World Health Organization has targeted elimination of chronic viral hepatitis for most of the world by 2030. Yet many remain in the US with screening, diagnosing and treating both hepatitis B and C. Those that bear a direct relationship to public policy include training physicians to manage hepatitis B and increasing access to treatment and raising awareness of chronic hepatitis C.
The lack of awareness about the prevalence of chronic viral hepatitis in the United States and about the proper methods and target populations for screening and medical management of chronic hepatitis B and hepatitis C contributes to continuing transmission; missing of opportunities for prevention, including vaccination; missing of opportunities for early diagnosis and medical care; and poor health outcomes in infected people.
Course Objectives:
• Discuss the prevalence and incidence of acute and chronic hepatitis B and hepatitis C both in the general US population and in at-risk populations.
• Review the history, epidemiology, demographics, natural history, histology, immunology and pathophysiology of the viral infection.
• Discuss state-of-the-art diagnostic and treatment guidelines for both hepatitis B and C.
• Formulate and/or implement strategies for preventing, diagnosing, treating, and/or referring patients with HBV and/or HCV.
• Evaluate the multidisciplinary team approach to care of patients with hepatitis B and C.
• Establish a local network of practitioners for information sharing, referrals, etc.
• Improve the health of patients infected with the HBV and/or HCV virus.
Speakers: Steven Han, MD, UCLA, Jeff Kahn, MD, University of Southern California
Time: 7:30 am - 5:00 pm
Additional details will be posted as soon as they are available.
Course Description:
The Scripps National Hepatitis B & C Training Program and Treatment Update will contribute towards increasing the number of health care practitioners educated on the prevalence of chronic viral hepatitis, as well as those properly preventing, diagnosing, treating, and/or referring patients with chronic illness; therefore contributing towards prevention of new cases and improved management of already infected patients.
Viral hepatitis is the seventh leading cause of death in the world, killing more people than traffic injuries, HIV and AIDS, or diabetes. Every year chronic viral hepatitis, of which hepatitis B and C are the most common forms, kills a million people, roughly 20,000 of them in the United States. These deaths could be prevented. Hepatitis B vaccine conveys 95 percent immunity, and new therapies for hepatitis C cure the vast majority of patients. A report from the National Academies of Sciences, Engineering, and Medicine, released in April, 2016 concluded that both hepatitis B and C could be rare diseases in the United States, and a report from the World Health Organization has targeted elimination of chronic viral hepatitis for most of the world by 2030. Yet many remain in the US with screening, diagnosing and treating both hepatitis B and C. Those that bear a direct relationship to public policy include training physicians to manage hepatitis B and increasing access to treatment and raising awareness of chronic hepatitis C.
The lack of awareness about the prevalence of chronic viral hepatitis in the United States and about the proper methods and target populations for screening and medical management of chronic hepatitis B and hepatitis C contributes to continuing transmission; missing of opportunities for prevention, including vaccination; missing of opportunities for early diagnosis and medical care; and poor health outcomes in infected people.
Course Objectives:
• Discuss the prevalence and incidence of acute and chronic hepatitis B and hepatitis C both in the general US population and in at-risk populations.
• Review the history, epidemiology, demographics, natural history, histology, immunology and pathophysiology of the viral infection.
• Discuss state-of-the-art diagnostic and treatment guidelines for both hepatitis B and C.
• Formulate and/or implement strategies for preventing, diagnosing, treating, and/or referring patients with HBV and/or HCV.
• Evaluate the multidisciplinary team approach to care of patients with hepatitis B and C.
• Establish a local network of practitioners for information sharing, referrals, etc.
• Improve the health of patients infected with the HBV and/or HCV virus.
Speakers: Steven Han, MD, UCLA, Jeff Kahn, MD, University of Southern California
Time: 7:30 am - 5:00 pm
Additional details will be posted as soon as they are available.
KEY DATES
06 Oct, 2018
Event Start Date
06 Oct, 2018
Event End Date
SPECIALITIES
Infectious DiseaseGastroenterologySUGGESTED HOTELS
CONFERENCE VENUE
Sheraton Universal HotelRELATED CONFERENCES & LIVE WEBINARS
Quick Links